SEC Form 4 · accession 0001193125-26-269397
Xilio Therapeutics, Inc. · XLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert W. Ross
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001840233
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.99 | Jun 11, 2026 | A | 5,000 | A | — | Jun 10, 2036 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.